What kind of targeted drug is ivonib used to treat and how to take it?

Ivosidenib (Ivosidenib) is a targeted drug used to treat patients with a specific type of leukemia or cholangiocarcinoma, namely acute myeloid leukemia (AML) with cytogenetic abnormalities and myelodysplastic syndrome (IDH1) mutation-positive patients. This mutation is common in some AML patients, and ivonib can help control the progression of the disease by targeting and inhibiting the mutated IDH1 gene.

The recommended dose of ivonib is 500 mg orally once daily until disease progression or unacceptable toxicity occurs. For patients with acute myeloid leukemia or myelodysplastic syndrome who do not have disease progression or unacceptable toxicity, ivosidenib should be continued for at least 6 months to allow time for clinical response. Do not use ivosidenib with a high-fat meal, with or without food.

For newly diagnosed acute myeloid leukemia (combination regimen), start in combination with azacitidine 75 mg/m2 subcutaneously or intravenously on days 1-7 (or days 1-5 and 8-9) of each 28-day cycle. Please see the azacitidine prescribing information for more dosing information.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.